Resource Summary Report

Generated by FDI Lab - SciCrunch.org on May 11, 2025

InVivoPlus anti-mouse NK1.1

RRID:AB_1107737 Type: Antibody

Proper Citation

(Bio X Cell Cat# BE0036, RRID:AB_1107737)

Antibody Information

URL: http://antibodyregistry.org/AB_1107737

Proper Citation: (Bio X Cell Cat# BE0036, RRID:AB_1107737)

Target Antigen: NK1.1

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: in vivo NK cell depletion, Flow cytometry Consolidation on 12/2021: AB_1107737, AB_2894792.

Antibody Name: InVivoPlus anti-mouse NK1.1

Description: This monoclonal targets NK1.1

Target Organism: mouse

Clone ID: clone PK136

Antibody ID: AB_1107737

Vendor: Bio X Cell

Catalog Number: BE0036

Alternative Catalog Numbers: BE0036-25MG, BE0036-100MG, BE0036-5MG, BP0036-100MG, BP0036-25MG, BE0036-50MG, BP0036-5MG, BP0036-50MG, BE0036-1MG

Record Creation Time: 20231110T031700+0000

Record Last Update: 20240725T090714+0000

Ratings and Alerts

No rating or validation information has been found for InVivoPlus anti-mouse NK1.1.

No alerts have been found for InVivoPlus anti-mouse NK1.1.

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 78 mentions in open access literature.

Listed below are recent publications. The full list is available at FDI Lab - SciCrunch.org.

Liu W, et al. (2024) SGLT2 inhibitor promotes ketogenesis to improve MASH by suppressing CD8+ T cell activation. Cell metabolism, 36(10), 2245.

Tsao HW, et al. (2024) Targeting the aminopeptidase ERAP enhances antitumor immunity by disrupting the NKG2A-HLA-E inhibitory checkpoint. Immunity, 57(12), 2863.

Chun D, et al. (2024) Flt3L enhances clonal diversification and selective expansion of intratumoral CD8+ T cells while differentiating into effector-like cells. Cell reports, 43(12), 115023.

Collins A, et al. (2024) Maternal inflammation regulates fetal emergency myelopoiesis. Cell, 187(6), 1402.

Chang YH, et al. (2024) SETDB1 suppresses NK cell-mediated immunosurveillance in acute myeloid leukemia with granulo-monocytic differentiation. Cell reports, 43(8), 114536.

Russick J, et al. (2024) Tumor stage-driven disruption of NK cell maturation in human and murine tumors. iScience, 27(11), 111233.

Pedde AM, et al. (2024) Tissue-colonizing disseminated tumor cells secrete prostaglandin E2 to promote NK cell dysfunction and evade anti-metastatic immunity. Cell reports, 43(11), 114855.

Li Y, et al. (2024) Tumor cells impair immunological synapse formation via central nervous system-enriched metabolite. Cancer cell, 42(6), 985.

Jiao M, et al. (2024) Targeting Catechol-O-Methyltransferase Induces Mitochondrial Dysfunction and Enhances the Efficacy of Radiotherapy in Glioma. Cancer research, 84(21), 3640.

Shi W, et al. (2024) Next-generation anti-PD-L1/IL-15 immunocytokine elicits superior antitumor immunity in cold tumors with minimal toxicity. Cell reports. Medicine, 5(5), 101531.

Beck JD, et al. (2024) Long-lasting mRNA-encoded interleukin-2 restores CD8+ T cell neoantigen immunity in MHC class I-deficient cancers. Cancer cell.

van Elsas MJ, et al. (2024) Immunotherapy-activated T cells recruit and skew late-stage activated M1-like macrophages that are critical for therapeutic efficacy. Cancer cell, 42(6), 1032.

Xue G, et al. (2024) Clinical drug screening reveals clofazimine potentiates the efficacy while reducing the toxicity of anti-PD-1 and CTLA-4 immunotherapy. Cancer cell.

Subramanian S, et al. (2024) Microbiota regulates neonatal disease tolerance to virusevoked necrotizing enterocolitis by shaping the STAT1-NLRC5 axis in the intestinal epithelium. Cell host & microbe, 32(10), 1805.

Colucci M, et al. (2024) Retinoic acid receptor activation reprograms senescence response and enhances anti-tumor activity of natural killer cells. Cancer cell.

Jiao M, et al. (2024) VHL loss enhances antitumor immunity by activating the anti-viral DNAsensing pathway. iScience, 27(7), 110285.

Li Y, et al. (2024) IGSF8 is an innate immune checkpoint and cancer immunotherapy target. Cell, 187(11), 2703.

Sun X, et al. (2024) Deletion of the mRNA endonuclease Regnase-1 promotes NK cell antitumor activity via OCT2-dependent transcription of Ifng. Immunity, 57(6), 1360.

Guo HZ, et al. (2024) A CD36-dependent non-canonical lipid metabolism program promotes immune escape and resistance to hypomethylating agent therapy in AML. Cell reports. Medicine, 5(6), 101592.

Borys SM, et al. (2024) NK cells restrain cytotoxic CD8+ T cells in the submandibular gland via PD-1-PD-L1. Science immunology, 9(102), eadl2967.